HK1172327A1 - 作為 激酶抑制劑的含氮雜芳基衍生物 - Google Patents

作為 激酶抑制劑的含氮雜芳基衍生物

Info

Publication number
HK1172327A1
HK1172327A1 HK12113100.6A HK12113100A HK1172327A1 HK 1172327 A1 HK1172327 A1 HK 1172327A1 HK 12113100 A HK12113100 A HK 12113100A HK 1172327 A1 HK1172327 A1 HK 1172327A1
Authority
HK
Hong Kong
Prior art keywords
jak3
kinase inhibitors
containing heteroaryl
heteroaryl derivatives
derivatives
Prior art date
Application number
HK12113100.6A
Other languages
English (en)
Inventor
卡門．阿爾曼薩．羅薩萊斯
豪爾赫．薩拉斯．索拉納
羅伯特．薩利維．薩利維
塞爾吉奧．羅德裏格斯．艾斯克裏奇
瑪麗亞．克裏斯蒂娜．斯克雷．岡薩雷斯
Original Assignee
維克特拉有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 維克特拉有限公司 filed Critical 維克特拉有限公司
Publication of HK1172327A1 publication Critical patent/HK1172327A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK12113100.6A 2009-10-29 2012-12-19 作為 激酶抑制劑的含氮雜芳基衍生物 HK1172327A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09382233 2009-10-29
US29105109P 2009-12-30 2009-12-30
US32992710P 2010-04-30 2010-04-30
PCT/EP2010/066476 WO2011051452A1 (en) 2009-10-29 2010-10-29 N-containing heteroaryl derivatives as jak3 kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1172327A1 true HK1172327A1 (zh) 2013-04-19

Family

ID=41571618

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12113100.6A HK1172327A1 (zh) 2009-10-29 2012-12-19 作為 激酶抑制劑的含氮雜芳基衍生物

Country Status (23)

Country Link
US (2) US8501735B2 (zh)
EP (1) EP2493895B1 (zh)
JP (1) JP5759471B2 (zh)
KR (1) KR101675614B1 (zh)
CN (1) CN102712658B (zh)
AR (1) AR078833A1 (zh)
AU (1) AU2010311378B2 (zh)
BR (1) BR112012010186B8 (zh)
CA (1) CA2778680C (zh)
DK (1) DK2493895T3 (zh)
ES (1) ES2629006T3 (zh)
HK (1) HK1172327A1 (zh)
IL (1) IL219385A0 (zh)
MX (1) MX2012005100A (zh)
PE (1) PE20121352A1 (zh)
PL (1) PL2493895T3 (zh)
PT (1) PT2493895T (zh)
RU (1) RU2553681C2 (zh)
SI (1) SI2493895T1 (zh)
TW (1) TWI478714B (zh)
UA (1) UA109775C2 (zh)
WO (1) WO2011051452A1 (zh)
ZA (1) ZA201203090B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2397482A1 (en) * 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
US20130165426A1 (en) * 2010-07-06 2013-06-27 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
US9018395B2 (en) 2011-01-27 2015-04-28 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
WO2013025628A1 (en) * 2011-08-15 2013-02-21 Ligand Pharmaceuticals Incorporated Janus kinase inhibitor compounds and methods
WO2013078126A1 (en) 2011-11-23 2013-05-30 Cancer Research Technology Limited Thienopyrimidine inhibitors of atypical protein kinase c
WO2013117649A1 (en) * 2012-02-10 2013-08-15 Galapagos Nv Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases
UY34615A (es) * 2012-02-10 2013-09-30 Galapagos Nv Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
TW201513861A (zh) * 2013-01-17 2015-04-16 Galapagos Nv 用於治療退化性及發炎疾病之新穎化合物
WO2014145852A2 (en) 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
US9067914B1 (en) 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
WO2015143161A1 (en) 2014-03-20 2015-09-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
DK3572405T3 (da) 2014-09-12 2023-10-16 Biohaven Therapeutics Ltd Benzoimidazol-1,2-yl-amider som kv7-kanalaktivatorer
AU2015364557C1 (en) 2014-12-18 2021-11-18 Genzyme Corporation Pharmaceutical formulations of tropomyosin related kinase (Trk) inhibitors
EP3053927A1 (en) 2015-02-05 2016-08-10 Vectura Limited Novel polymorphs
WO2016142201A1 (en) 2015-03-10 2016-09-15 Vectura Limited Crystalline form of a jak3 kinase inhibitor
JP6964343B2 (ja) 2015-11-20 2021-11-10 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ１阻害剤としてのプリノン
CN111465602B (zh) 2017-10-17 2023-05-23 帕劳制药有限公司 4-氨基嘧啶化合物的合成
TWI820146B (zh) 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN112724133B (zh) * 2021-01-12 2022-03-25 湖南复瑞生物医药技术有限责任公司 6-溴吡唑并[1,5-a]吡啶的制备方法
WO2023248010A2 (en) 2022-06-23 2023-12-28 Synovo Gmbh Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases
WO2024119058A2 (en) 2022-12-02 2024-06-06 Kinaset Therapeutics, Inc. Formulation of a pan-jak inhibitor

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
JP4681451B2 (ja) 2002-10-28 2011-05-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤としてのヘテロアリールオキシ置換フェニルアミノピリミジン類
EP1505064A1 (en) 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
AR050188A1 (es) * 2004-08-03 2006-10-04 Uriach Y Compania S A J Compuestos heterociclicos condensados utiles en terapia como inhibidores de quinasas p38 y composiciones farmaceuticas que los contienen
US7718801B2 (en) * 2004-08-31 2010-05-18 Banyu Pharmaceutical Co., Ltd. Substituted imidazole derivative
US7919487B2 (en) 2004-11-10 2011-04-05 Synta Pharmaceuticals Corporation Heteroaryl compounds
RU2007140903A (ru) 2005-04-05 2009-05-20 Фармакопия, Инк. (Us) Производные пурина и имидазопиридина для иммуносупрессии
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
KR20080004585A (ko) 2005-04-08 2008-01-09 바이엘 파마슈티칼스 코포레이션 피리미딘 유도체 및 암의 치료에서의 이의 용도
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
RU2008117151A (ru) * 2005-09-30 2009-11-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Деазапурины, пригодные в качестве ингибиторов янус-киназ
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7915268B2 (en) 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
WO2008043031A1 (en) 2006-10-04 2008-04-10 Pharmacopeia, Inc. 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
ES2627352T3 (es) 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
KR20100014271A (ko) 2006-11-16 2010-02-10 파마코페이아, 엘엘씨. 면역 억제를 위한 7-치환된 퓨린 유도체
CN101679440A (zh) * 2007-04-02 2010-03-24 帕劳制药股份有限公司 作为jak3抑制剂的吡咯并嘧啶衍生物
CA2686485A1 (en) 2007-05-23 2008-11-27 Pharmacopeia, Llc Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
WO2009048474A1 (en) 2007-10-12 2009-04-16 Pharmacopeia, Inc. 2,7,9-substituted purinone derivatives for immunosuppression
WO2009068512A1 (en) 2007-11-30 2009-06-04 Palau Pharma, S. A. 2 -amino-pyrimidine derivatives as histamine h4 antagonists
PE20091524A1 (es) 2007-12-19 2009-09-25 Palau Pharma Sa Derivados de 2-aminopirimidina
KR101639819B1 (ko) 2007-12-21 2016-07-14 팔라우 파르마 에스에이 히스타민 ｈ４ 수용체 길항제로서 ４-아미노피리미딘 유도체
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
EP2516420B8 (en) 2009-12-23 2018-10-17 Medicis Pharmaceutical Corporation Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物

Also Published As

Publication number Publication date
PE20121352A1 (es) 2012-10-15
PL2493895T3 (pl) 2017-10-31
US20120245140A1 (en) 2012-09-27
ES2629006T3 (es) 2017-08-07
ZA201203090B (en) 2013-09-25
AU2010311378B2 (en) 2014-04-24
DK2493895T3 (en) 2017-08-14
EP2493895B1 (en) 2017-04-26
IL219385A0 (en) 2012-06-28
MX2012005100A (es) 2012-06-08
TWI478714B (zh) 2015-04-01
KR20120101402A (ko) 2012-09-13
TW201127385A (en) 2011-08-16
BR112012010186B1 (pt) 2020-11-03
BR112012010186A2 (pt) 2016-04-19
US20130289015A1 (en) 2013-10-31
KR101675614B1 (ko) 2016-11-11
PT2493895T (pt) 2017-07-05
BR112012010186B8 (pt) 2021-05-25
WO2011051452A1 (en) 2011-05-05
CA2778680C (en) 2016-12-13
JP2013509382A (ja) 2013-03-14
RU2553681C2 (ru) 2015-06-20
US20130131038A9 (en) 2013-05-23
UA109775C2 (xx) 2015-10-12
US8501735B2 (en) 2013-08-06
US8946257B2 (en) 2015-02-03
SI2493895T1 (sl) 2017-10-30
AR078833A1 (es) 2011-12-07
JP5759471B2 (ja) 2015-08-05
AU2010311378A1 (en) 2012-05-24
RU2012122020A (ru) 2013-12-10
EP2493895A1 (en) 2012-09-05
CN102712658A (zh) 2012-10-03
CA2778680A1 (en) 2011-05-05
CN102712658B (zh) 2015-06-03

Similar Documents

Publication Publication Date Title
HK1172327A1 (zh) 作為 激酶抑制劑的含氮雜芳基衍生物
HK1162022A1 (zh) 作為激酶抑制劑的吡啶甲酰胺衍生物
ZA201100344B (en) Pyrimidine derivatives as kinase inhibitors
HRP20130698T1 (en) Novel phenylpyrazinones as kinase inhibitors
IL218271A0 (en) Heterocyclic compounds as janus kinase inhibitors
HRP20130787T1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
IL213906A0 (en) Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
IL210990A0 (en) Piperidine derivatives as jak3 inhibitors
IL208716B (en) The history of phosphorus as kinase inhibitors
IL210292A0 (en) Heteroaryl derivatives as dgat1 inhibitors
HK1151291A1 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL218114A0 (en) 5-6-bicyclic heteroaryl-cotaining urea compounds as kinase inhibitors
IL210573A0 (en) Compounds as kinase inhibitors
IL212842A0 (en) Azaindole derivatives as kinase inhibitors
IL220205A0 (en) Heterocyclic compounds as janus kinase inhibitors
EP2231152A4 (en) THIENOPYRANONES AS KINASE INHIBITORS
EP2611806A4 (en) HETEROCYCLIC COMPOUNDS ENRICHED IN DEUTERIUM AS INHIBITORS OF KINASES
HK1156611A1 (zh) 用作 激酶抑制劑的萘啶酮
EP2432321A4 (en) THIAZOLOPYRIMIDINONE DERIVATIVES AS INHIBITORS OF PI3 KINASE